CEO Jim Clemmer said the company has spent the last several years reshaping its portfolio and operating model, moving away ...
AxoGen (NASDAQ:AXGN) executives outlined a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果